Aurora kinase - mTOR signaling in sarcomatoid mRCC ͳ RNA-seq Reveals Aurora Kinase Driven-mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma Sumanta K. Pal, 1 Miaoling He 2 , Tommy Tong, 3 Huiqing Wu, 3 Xueli Liu, 4 Clayton Lau, 5 Jin-Hui Wang, 6 Charles Warden, 6 Xiwei Wu, 6 Sabina Signoretti, 7 Toni K. Choueiri, 8 Jose A. Karam, 9 Jeremy O. Jones 2 1 Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 2 Department of Molecular Pharmacology, City of Hope Comprehensive Cancer Center, Duarte, CA 3 Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 4 Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA 5 Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 6 Functional Genomics, City of Hope Comprehensive Cancer Center, Duarte, CA 7 Department of Pathology, Dana Farber Cancer Center, Boston, MA 8 Department of Medical Oncology, Dana Farber Cancer Center, Boston, MA 9 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX *Corresponding Author: Jeremy O. Jones, PhD Beckman Research Institute City of Hope Comprehensive Cancer Center 1500 East Duarte Road Duarte, CA 91010 Office: (626) 256-4673 Fax: (626) 301-8233 E-mail: jjones@coh.org Running Head: Aurora kinase - mTOR signaling in sarcomatoid mRCC Keywords: sarcomatoid, metastatic renal cell carcinoma, mTOR, aurora kinase, RNA-seq, VEGF signaling Conflict of Interest: The authors have no conflicts to disclose Total Words (Abstract Words): 4071 (177) Figures: 5 Tables: 3 on July 17, 2017. © 2014 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 2, 2014; DOI: 10.1158/1541-7786.MCR-14-0352